Trials / Conditions / Chronic Eosinophilic Leukemia

Chronic Eosinophilic Leukemia

21 registered clinical trials studyying Chronic Eosinophilic Leukemia.

Status	Trial	Sponsor	Phase
Completed	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015	City of Hope Medical Center	Phase 1
Withdrawn	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778	Roswell Park Cancer Institute	N/A
Completed	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Completed	Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or NCT01305200	Children's Oncology Group	Phase 3
Completed	Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia NCT01484015	Wake Forest University Health Sciences	Phase 1
Completed	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562	City of Hope Medical Center	—
Completed	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921	Martin, Paul	N/A
Terminated	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067	City of Hope Medical Center	Phase 2
Completed	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494	Wake Forest University Health Sciences	N/A
Completed	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747	National Cancer Institute (NCI)	Phase 1
Completed	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388	Roswell Park Cancer Institute	N/A
Completed	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769	Fred Hutchinson Cancer Center	Phase 2
Completed	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Phase 3
Completed	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203	Fred Hutchinson Cancer Center	Phase 2
Completed	3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, NCT00381550	National Cancer Institute (NCI)	Phase 2
Completed	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681	Fred Hutchinson Cancer Center	N/A
Completed	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305	National Cancer Institute (NCI)	Phase 1
Completed	Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes NCT00787384	Northern Italy Leukemia Group	Phase 2
Completed	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415	National Cancer Institute (NCI)	Phase 1
Completed	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593	Fred Hutchinson Cancer Center	N/A